Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-880 (zimislecel) in type 1 diabetes with impaired hypoglycemia awareness and severe hypoglycemia
NL-OMON59862Phase 3Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2023
- Modality
- Beta Cells → Tissue Cells → Other Cell Types → Cell Therapies, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of zimislecel in diabetes mellitus type 1 (T1D), sponsored by Vertex Pharmaceuticals. Started May 2023; status: recruiting.
02
Drugs
zimislecel
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON59862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59862.